185 related articles for article (PubMed ID: 1419908)
1. Protein prenylation: key to ras function and cancer intervention?
Khosravi-Far R; Cox AD; Kato K; Der CJ
Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908
[No Abstract] [Full Text] [Related]
2. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
3. Farnesylation of p21 Ras proteins in Xenopus oocytes.
Zhao J; Kung HF; Manne V
Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
[TBL] [Abstract][Full Text] [Related]
4. Ras farnesyltransferase: a new therapeutic target.
Leonard DM
J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
[No Abstract] [Full Text] [Related]
5. The prenylation of proteins.
Sinensky M; Lutz RJ
Bioessays; 1992 Jan; 14(1):25-31. PubMed ID: 1546978
[TBL] [Abstract][Full Text] [Related]
6. Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation.
Danesi R; McLellan CA; Myers CE
Biochem Biophys Res Commun; 1995 Jan; 206(2):637-43. PubMed ID: 7826382
[TBL] [Abstract][Full Text] [Related]
7. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins.
Macchia M; Jannitti N; Gervasi G; Danesi R
J Med Chem; 1996 Mar; 39(7):1352-6. PubMed ID: 8691464
[TBL] [Abstract][Full Text] [Related]
8. A yeast GTPase-activating protein that interacts specifically with a member of the Ypt/Rab family.
Strom M; Vollmer P; Tan TJ; Gallwitz D
Nature; 1993 Feb; 361(6414):736-9. PubMed ID: 8441469
[TBL] [Abstract][Full Text] [Related]
9. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
10. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
[No Abstract] [Full Text] [Related]
11. JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Luckman SP; Hughes DE; Coxon FP; Russell GG; Rogers MJ
J Bone Miner Res; 2005 Jul; 20(7):1265-74. PubMed ID: 16050006
[No Abstract] [Full Text] [Related]
12. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
Farh L; Mitchell DA; Deschenes RJ
Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
[TBL] [Abstract][Full Text] [Related]
13. Ras C-terminal processing enzymes--new drug targets?
Gibbs JB
Cell; 1991 Apr; 65(1):1-4. PubMed ID: 2013090
[No Abstract] [Full Text] [Related]
14. Reversion of a human tumour cell line containing oncogenic p21ras is associated with a defect in the post-translational processing of the ras protein.
Tilbrook PA; Paterson HF; Marshall CJ
Oncogene; 1995 Feb; 10(4):805-9. PubMed ID: 7862461
[TBL] [Abstract][Full Text] [Related]
15. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells.
Barlat I; Schweighoffer F; Chevallier-Multon MC; Duchesne M; Fath I; Landais D; Jacquet M; Tocque B
Oncogene; 1993 Jan; 8(1):215-8. PubMed ID: 7999142
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
17. Identification of a human guanine nucleotide-releasing factor (H-GRF55) specific for Ras proteins.
Schweighoffer F; Faure M; Fath I; Chevallier-Multon MC; Apiou F; Dutrillaux B; Sturani E; Jacquet M; Tocque B
Oncogene; 1993 Jun; 8(6):1477-85. PubMed ID: 7684828
[TBL] [Abstract][Full Text] [Related]
18. Novel isoprenoid modified proteins in Halobacteria.
Sagami H; Kikuchi A; Ogura K; Fushihara K; Nishino T
Biochem Biophys Res Commun; 1994 Sep; 203(2):972-8. PubMed ID: 8093082
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of farnesyltransferase and Ras processing peptidase.
Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
[TBL] [Abstract][Full Text] [Related]
20. Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid.
Kinsella BT; Erdman RA; Maltese WA
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8934-8. PubMed ID: 1924354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
